Clinical Trial Update: Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase I study of AZD2171 in combination with ZD1839 in patients with advanced cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AZD2171 (cediranib)
• ZD1839 (Gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Tumor | Phase 1 | Status: COMPLETED